Clinical Trial of BT02 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

BT02 monoclonal antibody injection

It is expected to include 10-30 patients assigned to dose escalation cohorts.

Trial Locations (1)

RECRUITING

Cancer Institute and Hospital, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER